Cargando…

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings

INTRODUCTION: ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India. METHODS: An audit of a prospectively collec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapoor, Akhil, Noronha, Vanita, Patil, Vijay, Menon, Nandini, Joshi, Amit, Kumar, Amit, Singh, Ajay Kumar, Mahajan, Abhishek, Janu, Amit, Kumar, Rajiv, Pai, Trupti, Chougule, Anuradha, Shetty, Omshree, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841022/ https://www.ncbi.nlm.nih.gov/pubmed/36654881 http://dx.doi.org/10.1016/j.jtocrr.2022.100443

Ejemplares similares

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
por: Khaddar, Satvik, et al.
Publicado: (2022)

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
por: Behel, Vichitra, et al.
Publicado: (2022)

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
por: Bondili, Suresh Kumar, et al.
Publicado: (2022)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

ALK1 Gene Rearranged Pulmonary Sarcomatoid Carcinoma Masquerading as Tuberculosis in a Young Male
por: Sahay, Ayushi, et al.
Publicado: (2021)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
por: Abhishek, Mahajan, et al.
Publicado: (2022)

EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
por: Noronha, Vanita, et al.
Publicado: (2013)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
por: Noronha, Vanita, et al.
Publicado: (2017)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate, Shruti, et al.
Publicado: (2019)

Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience
por: Chougule, Anuradha, et al.
Publicado: (2023)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u8rf0loo2phvv57gubcke7fkjk